Efficacy Observation On The Treatment Of Chronic Hepatitis B, The Syndrome Of Liver-Kidney Yin Deficiency By Bushenqinggan Fang Combined With Telbivudine

Purpose:To observe the clinical efficacy on the treatment of Chronic Hepatitis B,the syndrome of Liver-Kidney Yin Deficiency by Bushenqinggan Fang combined with Telbivudine.Method:60 Hepatitis B patients as research subjects, were randomly divided into two groups. The experimental group (30 cases) was treated with Bushenqinggan Fang combined with Telbivudine, and the control group (30 cases) was treated with Telbivudine alone. After 24 weeks'treatment, to observe the patient's improvements such as:clinical symptom, biochemical indicator, immunity target, virology target, and so on.Results:After the treatment of 24 weeks, the total efficiency in the experimental group was 73.33%, which was higher than in the control group 53.33%. Statistically, there was not significant difference between the two groups (P>0.05), perhaps because of the short course. The experimental group was significantly better than the control group, in improving clinical symptom, biochemical indicator, immunity target, anti-viral response rate, which were statistically significantly different (P<0.05). In the HBV-DNA negative rate, HBeAg negative rate and HBeAg/HBeAb conversion rate, although the experimental group was higher than the other, Statistically, the two groups have not shown difference (P>0.05).Conclusion:The treatment method of Bushenqinggan Fang combined with Telbivudine is safe and effective in clinical applications of Chronic Hepatitis B, the syndrome of Liver-Kidney Yin Deficiency, not only in improving the symptoms of the patients, regulating their immunity and resuming their liver function, but also in enhancing anti-viral response rate. And it has not been found the obvious side effect.